| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest A1c Test Articles
Byetta Dusts Insulin In Year-Long Trial
Dec 11, 2007
In a recent randomized study, 69 people with type 2 diabetes who were already taking metformin were given either Byetta or Lantus for a full year. When the results were in, Byetta came out ahead on several fronts.
Byetta controlled blood sugar about as well as Lantus; both medicines reduced A1c's by slightly less than a point. But when it came to hypoglycemia, Byetta took the honors: 24.2 percent of the Lantus patients had an low blood sugar episode during the trial, compared to only 8.3 percent of the Byetta group.
Where Byetta really shone was in weight loss. The Byetta patients lost about eight pounds, but the Lantus group gained about two pounds.
With regard to beta cell function, Byetta won out as well. The patients' beta cell health was assessed by measuring their secretion of C-peptide, a byproduct of the body's own insulin output. After the year of treatment, the Byetta group could produce considerably more C-peptide than the Lantus group was able to manage, indicating that the Byetta group's beta cells were in robust health compared to the beta cells of the Lantus group.
Usually patients are started on Byetta at five micrograms twice a day for at least thirty days, but then later upped to ten micrograms twice daily. In this study, the Byetta doses were increased to as much as twenty micrograms three times a day, a dosage that is not yet approved by the FDA.
Source: Lilly Press Release, September 2007
Categories: A1c Test, Byetta, Insulin, Lantus, Low Blood Sugar, Type 2 Issues, Type 2 Medications
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
10 comments -
Dec 11, 2007 -
Email to a Friend
Send a link to this page to your friends and colleagues.